Saturday 17 October 2026
Export CLVSQ’s income statement to Excel — free account
Clovis Oncology, Inc.
CLVSQ Healthcare Biotechnology
Operating cash flow growth for five consecutive years.
Follow CLVSQ
Clovis Oncology, Inc. (CLVSQ) P/E ratio
Clovis Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (February 2023) to 0.0× (February 2023) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DARE Dare Bioscience, Inc. compare | n/m |
| TVRD Tvardi Therapeutics, Inc. compare | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| CLVSQ Clovis Oncology, Inc. | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)